NCT05469737: A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Sponsor: Bristol-Myers Squibb. Phase: PHASE2. Conditions: Myelodysplastic Syndromes